Pacific Edge reviews US pricing for new Cxbladder test, trading halted

Pacific Edge reviews US pricing for new Cxbladder test, trading halted
Pacific Edge says Cxbladder Triage Plus delivers “significant performance improvements” compared to its existing tests. (Image: Pacific Edge)
Rebecca Howard
Pacific Edge has been placed on a trade halt while it reviews draft gapfill or reimbursement rates for its new Cxbladder Triage Plus test from the US Centres for Medicare and Medicaid Services.“[It said it's] reviewing the prices and the associated documentation and needs time to assess the implications of them, consult with its advisers and industry partners, and prepare an announcement that provides context to investors.”Gapfill prices are proposed reimbursement rates for new or unpriced clinical diagnostic laboratory tests.Th...

More Markets

Another solar farm gets the nod from Genesis
Markets

Another solar farm gets the nod from Genesis

Genesis Energy has approved the construction of the Edgecumbe Solar Farm in the Bay of Plenty, marking its second major solar commitment in as many months.The company made a final investment decision (FID) on the 136 megawatt peak (MWp) farm, clearing the way for work to begin sh...

NZ’s Mighty Ape still weighing on ASX parent Kogan
Markets

NZ’s Mighty Ape still weighing on ASX parent Kogan

Management expects Mighty Ape to return to profitability in the second half of FY26.

Nvidia slump drags Wall Street and NZ sharemarket lower
Markets Market Close

Nvidia slump drags Wall Street and NZ sharemarket lower

The S&P/NZX 50 Index closed 20 points or 0.15% down at 13,419.40.

Jamie Gray 21 Nov 2025